**Specifications Table**TableSubject area*Cell biology; Health science*More specific subject area*Apoptosis; Ovarian cancer*Type of data*Table and figure*How data was acquired*Tissue microarray, human EOC cell lines OVCAR-3 and SK-OV-3 (ATCC, Manassas, VA, USA), Transfection, Western blot, Flow cytometry (Becton Dickinson Beckman Coulter, Inc., Brea, CA, USA)*Data format*Analyzed*Experimental factors*Cells were transfected with siRNA or shRNA; Cells were treated with 10* *ng/ml TGF-β1 for 24 h*Experimental features*The tissue microarray included 100 paraffin-embedded ovarian tissues; Screen 9 miRNAs that potentially target CMPK1*Data source location*Shanghai, China*Data accessibility*The data are with this article*Related research article*Zhou et al.*[@bib1]*"Cytidine monophosphate kinase is inhibited by the TGF-β signalling pathway through the upregulation of miR-130b-3p in human epithelial ovarian cancer" j.cellsig 35:197--207.*

**Value of the data**•Data present CMPK as an ovarian serous tumor progression marker.•The location of CMPK protein expression in the cytoplasm and nucleus of epithelial-type ovarian tumor cells is shown.•Suppression of CMPK affects the doubling time of EOC cells.•Data describe for the first time that knockdown of CMPK influences EOC cell apoptosis.•Data show the effect of CMPK-shRNA on TGF-β-induced Smad2 phosphorylation.

1. Data {#s0005}
=======

The data represent the observation from experiments of tissue microarray, Western blot and flow cytometry. Data in [Table 1](#t0005){ref-type="table"} are the list of sequences of siRNA, shRNA, miRNA and PCR primer used in a related research article [@bib1]. The data of the association of CMPK protein expression with clinicopathological features of patients with epithelial ovarian tumours are shown in [Table 2](#t0010){ref-type="table"}. Data in [Fig. 1](#f0005){ref-type="fig"} show the positive rate for CMPK staining in the cytoplasm and nucleus. [Fig. 2](#f0010){ref-type="fig"} confirms the knockdown of CMPK protein by Western blot after CMPK-siRNA transfection in OVCAR-3 and SK-OV-3 cells. Doubling times (DT) based on the optical density (OD) values at the time of measurement is shown in [Fig. 3](#f0015){ref-type="fig"}. Data in [Fig. 4](#f0020){ref-type="fig"} represent the proportion of early apoptotic cells detected by flow cytometry and the expression of cleaved caspase-3 protein, an active form of apoptotic protein, detected by Western blot after CMPK-shRNA infection. Data of phospho-Smad2 detection by Western blot are shown in [Fig. 5](#f0025){ref-type="fig"}. Screening data of the effect of miRNAs on CMPK expression are shown in [Fig. 6](#f0030){ref-type="fig"}.Fig. 1Evaluation of positive rate for CMPK staining in tissue microassay. CMPK protein staining in subcellular localization was scored. Histogram shows the positive rate of CMPK staining in different tissues. A positive staining of CMPK was found in the cytoplasm and nucleus of ovarian tumor cells, whereas normal tissue appeared negative staining. Data are presented as mean. N, case number; Normal, normal ovarian tissue; Benign, benign tumor; Borderline, borderline tumor; Malignant, malignant tumor.Fig. 1Fig. 2Knockdown of CMPK expression in EOC cells is confirmed by Western blot after siRNA transfection. OVCAR-3 (A, C) and SK-OV-3 (B, D) cells were transiently transfected with CMPK-siRNA (CMPK-siR) and negative control-siRNA (NC-siR), respectively. Untreated cells were used as blank control (Blank). (A, B) CMPK protein was detected by Western blot at 24 h post-transfection. (C, D) Histograms show semi-quantitative analysis after densitometry on the gels of (A) and (B), respectively. Data are presented as mean ± SEM (N = 3). \*P\<0.05; \*\*P\<0.01 (CMPK-siRNA *vs.* Blank or NC-siR).Fig. 2Fig. 3Doubling times (DT) based on the OD values at the time of measurement. (A) Histogram shows the DT (h, hour) of OVCAR-3 cells: Blank, 24.52±0.74; CTL, 23.91±0.82; NC, 30.07±3.02; CMPK-siR, 46.32±2.03. (B) Histogram shows the DT of SK-OV-3: Blank, 24.02±1.41; CTL, 25.06±2.06; NC, 26.19±1.64; CMPK-siR, 46.46±7.80. \*P\<0.05 (CMPK-siRNA group *vs.* other groups). Blank, control without transfection; CTL, reagent control, NC, negative control of transfection; CMPK-siR, CMPK-siRNA transfection.Fig. 3Fig. 4Suppression of CMPK influences EOC cell apoptosis. OVCAR-3 cells were infected with CMPK-shRNA lentiviral particles or empty vector lentiviral particles. (A) The proportion of apoptotic cells of OVCAR-3 CMPK-shRNA expressing cells (CMPK-shRNA) and negative control cells (NC) was determined by flow cytometry. (B) Histogram shows the quantitative analysis of the percentage of early apoptotic cells from (A). (C) Cleaved caspase-3 and full sized caspase-3 proteins in NC and CMPK-shRNA cells were detected by Western blot. (D) Histogram shows the semi-quantitative analyses of the gels from (C) after densitometry (N = 3). Data are presented as mean±SEM. \*P\<0.05; \*\*P\<0.01 (CMPK-shRNA *vs.* NC).Fig. 4Fig. 5Effect of CMPK-shRNA on TGF-β-induced Smad2 phosphorylation. (A) Expression of protein detected by Western blot. (B, C) Histogram shows the semi-quantitative analyses of pSmad2 in OVCAR-3 and SK-OV-3 cells after densitometry in the gels from (A). Data are presented as mean±SEM. Different superscripts denote a significant difference from each other (P\<0.05; N=3).Fig. 5Fig. 6Effect of miRNAs on CMPK expression. CMPK protein expression was detected by Western blot. OVCAR-3 and SK-OV-3 cells were transiently transfected with nine miRNA mimics. Negative control miRNA (miR-NC) was used as control. Experiment was repeated twice.Fig. 6Table 1Sequences of siRNA, shRNA, miRNA and PCR primer.Table 1:NameSequence (5' → 3')Target positionCMPK-siRNASenseGAAAGAUUGUACCAGUUGAttnt 424--442AntisenseUCAACUGGUACAAUCUUUCttNC-siRNASenseUUCUCCGAACGUGUCACGUTTScrambleAntisenseACGUGACACGUUCGGAGAATTCMPK-shRNASensegatccGAAAGATTGTACCAGTTGAttcaagagaTCAACTGGTACAATCTTTCttttttgnt 424--442AntisenseaattcaaaaaaGAAAGATTGTACCAGTTGAtctcttgaaTCAACTGGTACAATCTTTCgmiR-130b-3pmiR-130b mimicCAGUGCAAUGAUGAAAGGGCAUnt 1824--1834miR-CtrlUCACAACCUCCUAGAAAGAGUAGAanti-miR-130bAUGCCCUUUCAUCAUUGCACUGnt 1824--1834anti-CtrlUCUACUCUUUCUAGGAGGUUGUGACMPK PCR primerForwardTGTCAGCTCCCTCAGCGTCnt 114--132ReverseCGAGGACGAACACGACCAGnt 255--273β-actin PCR primerForwardCATTGCCGACAGGATGCAGnt 1008--1026ReverseCTCGTCATACTCCTGCTTGCTGnt 1155--1176miR-130b-3p primerForwardGGCAGTGCAATGATGAAAGGReverseGTGCAGGGTCCGAGGTU6 primerForwardCTCGCTTCGGCAGCACAReverseAACGCTTCACGAATTTGCGTmiR-130b RT primerGTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACatgccc[^1]Table 2Association of CMPK protein expression with clinicopathological features of patients with epithelial ovarian tumours.Table 2:Clinicopathological featuresnTotal CMPK expressionP-valuePositive (%)Negative (%)Age0.221[a](#tbl2fna){ref-type="table-fn"}≤452611 (42.31)15 (57.69)\>454928 (57.14)21 (42.86)Histological typeSerous tumour440.005[b](#tbl2fnb){ref-type="table-fn"}Benign50 (00.00)5 (100.00)Borderline55 (100.00)0 (00.00)Malignant3414 (41.18)20 (58.82)Mucinous tumour140.748[b](#tbl2fnb){ref-type="table-fn"}Benign93 (33.33)6 (66.67)Borderline21 (50.00)1 (50.00)Malignant32 (66.67)1 (33.33)Endometrioid adenocarcinoma108 (80.00)2 (20.00)Transitional cell carcinoma44 (100.00)0 (00.00)Adenocarcinoma32 (66.67)1 (33.33)FIGO stage0.778[b](#tbl2fnb){ref-type="table-fn"}I2413 (54.17)11 (45.83)II106 (60.00)4 (40.00)III1910 (52.62)9 (47.37)IV11 (100.00)0 (00.00)[^2][^3][^4]

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Tissue microarray {#s0015}
----------------------

Ovarian tissue microarray (TMA) was obtained from Xi׳an Alena Biotechnology Ltd., Co. (Xi'an, Shanxi, China). Association of CMPK protein expression with clinicopathological features of patients with EOC was analyzed after immunohistochemistry staining.

2.2. Cell culture, treatment with TGF-β and transduction {#s0020}
--------------------------------------------------------

OVCAR-3 and SK-OV-3 cells (ATCC, Manassas, VA, USA) were cultured in RPMI-1640 and DMEM (Corning Inc., Manassas, VA, USA), respectively. The cells were treated with 10 ng/ml of recombinant human TGF-β1 (R&D Systems, Minneapolis, MN, USA) for 24 hours. Small interfering RNA (siRNA) was purchased from GenePharma Company (Shanghai, China). The cells were transiently transfected with siRNA mixture (Roche Applied Science, Indianapolis, IN, USA) for 5 h. CMPK-shRNA was constructed with double-strand oligonucleotides. The efficiency of CMPK-shRNA lentiviral transduction was examined by fluorescence microscopy as the construct contains green fluorescent protein (GFP). Knockdown of CMPK was confirmed by qRT-PCR and Western blot.

2.3. Transfection of miRNA mimics {#s0025}
---------------------------------

Nine miRNA mimics and negative control miRNA were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, Guangdong, China). The cells were transfected with miRNA mimics for 5 h and then incubated in a complete medium for up to 72 hours.

2.4. Western blot {#s0030}
-----------------

Protein was detected by Western blot using antibodies specific to phospho-Smad2 and Smad2 (Cell Signalling Technology, Inc. Danvers, MA, USA), active caspase-3 and full sized caspase-3 (Abways Technology, Inc. Shanghai, China).

2.5. Flow cytometry {#s0035}
-------------------

Apoptotic cells were detected by staining cells with APC Annexin-V and propidium iodide (PI) using an Annexin-V Apoptosis Detection Kit (BD Pharminggen, San Diego, CA, USA). Lentivirus infected EOCs were seeded in a 6-well plate and were incubated for 24 hours. Both supernatant and attached cells were collected and resuspended in 100 µl of 1X binding buffer. After adding 5 µl of Annexin-V and/or 5 µl of PI, the cells were incubated in the dark at room temperature for 15 min. After adding 400 µl of 1X binding buffer, the cell population was analyzed by flow cytometry.
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=============================================
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[^1]: The target position in CMPK mRNA sequence (GenBank Accession: [NM_016308](ncbi-n:NM_016308){#ir0005}) and β-actin mRNA sequence (GenBank Accession: [NM_001101](ncbi-n:NM_001101){#ir0010}) is shown. Sequence in lowercase indicates a linker. NC, negative control; nt, nucleotide; PCR, polymerase chain reaction; siRNA, small interfering RNA; shRNA, short hairpin RNA.

[^2]: The expression of CMPK was detected by immunohistochemistry using tissue microarray. For comparison of CMPK expression associated with age, a χ^2^ test was applied

[^3]: For multiple comparisons of CMPK expression associated with and histological types and clinical stages, a Fisher׳s exact test was applied.

[^4]: n, number of cases; Positive, positive expression; Negative, negative expression; FIGO, International Federation of Gynaecological Oncologists. Normal ovarian tissues (n=19) showing a negation staining of CMPK are served as control.
